Arkolith/Insider Trading/TPTX/Form 4

Tombesi Paolo

EVP & Chief Financial OfficerTurning Point Therapeutics, Inc. (TPTX) · full profile →Form 4 · filed Aug 17, 2022
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 17, 2022Disposed to issuer(D)30K$76.00$2.3M0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 17, 2022Disposed to issuer(D)61K——0
Aug 17, 2022Disposed to issuer(D)59K——0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-22-046272) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML